Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

CLDX

Market Cap$1.46B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Celldex Therapeutics Inc.Celldex Therapeutics Inc.-8.2--25%--
$46.00

Target Price by Analysts

109.1% upsideCelldex Therapeutics Target Price DetailsTarget Price
$-1.89

Current Fair Value

108.6% downside

Overvalued by 108.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.46 Billion
Enterprise Value$1.45 Billion
Dividend Yield$0 (0%)
Earnings per Share$-2.45
Beta1.14
Outstanding Shares66,383,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-8.17
PEG-12.76
Price to Sales-
Price to Book Ratio2.2
Enterprise Value to Revenue191.87
Enterprise Value to EBIT-7.37
Enterprise Value to Net Income-9
Total Debt to Enterprise0
Debt to Equity0.01

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Celldex Therapeutics Inc.

CEO: Anthony Marucci

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...